Syngene concludes the acquisition of Biologics Manufacturing Facility from Emergent BioSolutions Inc.

Syngene International Limited ('Syngene'), today announced the conclusion of the acquisition of its first biologics site in the USA, which was announced on March 10, 2025. The state-of-the-art biologics facility, fitted with multiple monoclonal antibody (mAbs) manufacturing lines, was acquired by Syngene USA Inc., a wholly owned subsidiary of Syngene, from Emergent Manufacturing Operations Baltimore, LLC, a subsidiary of Emergent BioSolutions Inc., at a gross value of USD 36.5 million.

The new site will increase Syngene's total single-use bioreactor capacity to 50,000L for large molecule discovery, development, and manufacturing services. Additionally, it will provide Syngene's customers with continuity of supply from its four development and manufacturing facilities located in India and North America, offering services ranging from cell line development, process optimization and both clinical and commercial supply.

Shares of Syngene International Limited was last trading in BSE at Rs. 706.05 as compared to the previous close of Rs. 683.25. The total number of shares traded during the day was 14195 in over 1091 trades.

The stock hit an intraday high of Rs. 708.95 and intraday low of 687.00. The net turnover during the day was Rs. 9938607.00.

Source : Equity Bulls

Keywords

SyngeneInternational INE398R01022 Pharmaceuticals Acquisition Biologics ManufacturingFacility EmergentBioSolutionsInc